Eigen Therapeutics Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Eigen Therapeutics Inc. - overview
Established
2021
Location
Redwood City, CA, US
Primary Industry
Biotechnology
About
Based in California, US, and co-founded by Transon Nguyen (CEO) and Kamran Ali (CTO) in 2021, Eigen Therapeutics Inc. operates as a biotechnology company focused on priming therapies that make cancer cells more visible. In December 2022, the firm raised USD 7 million in seed funding led by investor First Round Capital, with participation from other investors Bioverge, Builders VC, First Round Capital, etc. The company is working on the development of co-therapies by modulating the expression of the target cell to make cancer cells or tumors more visible and vulnerable to treatment and healthy cells more resilient to treatment.
Eigen utilizes machine learning, robotics, and its custom-developed lab operations software to carry out its biology experiments. The company plans to utilize its December 2022 funding to develop priming therapies initially focused on hematological malignancies.
Current Investors
First Round Capital, Alumni Ventures Group, Builders VC
Primary Industry
Biotechnology
Sub Industries
Biotechnology, Oncology/Cancer Treatment, Therapeutic Devices, Diagnostic Equipment
Website
www.eigentx.com
Verticals
HealthTech
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.